删除或更新信息，请邮件至freekaoyan#163.com(#换成@)

上海交通大学医学院导师教师师资介绍简介-范建高

本站小编 Free考研考试/2021-01-02
导师姓名： 范建高 专业代码： 100201
性别： 男 专业名称： 内科学
培养单位： 附属新华医院 三级学科/
专业领域： 消化系病
导师类型： 博士生导师 专业学位导师： 兼
联系方式： 电话: ;手机:**
邮编： 200092 邮箱地址： fattyliver2004@126.com

研究方向 (点击浏览详细信息)
脂肪性肝病
肠道菌群、肠道炎症与肝病

社会任职
中华医学会肝病学会委员、脂肪肝和酒精性肝病学组名誉组长
中国医师协会内科分会委员
中国医师协会脂肪肝专家委员会主任委员
《肝脏》等杂志副主编
上海市医学会肝病学分会名誉主任委员
World J Gastroenterol, Clinical Molcelular Hepatol, J Clinical Trans Hepatol, J Gastroenterol Hepatol，Alcohol, J DIG DIS, HBPD Int 编委或分册编辑
《胃肠病学和肝病学杂志》共同主编
中国医师协会医学普及分会委员\肝病科普专业委员会主任委员
中国医药生物技术协会慢病管理分会主任委员
海峡两岸医药卫生交流协会消化分会常委，肝病分会常委
白求恩公益基金会肝胆专业委员会副主任委员
上海市中西医结合学会器官纤维化专业委员会副主委
实用肝脏病杂志 总编辑
上海市医学会内科学分会常务委员
亚太肝病诊疗技术联盟监事长暨上海市联盟理事长
中国药师协会罕见病用药工作委员会副主任委员
中华医学会肝脏病分会委员
中华内科杂志，中华消化杂志，中华肝脏病杂志，中华糖尿病杂志，中国实用内科杂志、中国动脉硬化杂志等编委/常委
国际动脉硬化学会中国分会理事，中国病理生理学会动脉硬化专业委员会委员

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
2020 以青蒿为案例开展天然药物的转化医学研究：青蒿 上海交通大学STAR计划子课题 2020-01~2021-09 80万元 课题负责人
** 短链脂肪酸介导“菌群-宿主对话”恢复肝脏免疫耐受状态 国家自然科学基金 2019-01~2022-12 58万元 课题负责人
** 靶向肠道菌群精准诊疗非酒精性脂肪性肝病 上海市领军人才培养计划 2017-12~2019-12 80万元 课题负责人
2017YFSF090203 靶向肠道菌群诊断和治疗NASH的精准研究 国家科技部精准诊疗项目 2017-07~2020-12 300万元 课题负责人
** 通过“肠道菌群移植”重建粘膜免疫稳态对非酒精性脂肪性肝炎的防治研究 国家自然科学基金委 2015-01~2018-12 75万元 课题负责人
2013消化疾病学术研讨会 国家自然科学基金委 2013-11~2013-11 1.5万元 课题负责人
2013 上海国际消化系统会议 上海市科学技术委员会 2013-04~2014-12 20万元 课题负责人
** K细胞靶向性GLPs修饰以重塑“肝肠对话”模式对非酒精性脂肪性肝炎的干预研究 国家自然科学基金 2013-01~2016-12 70万元 课题负责人
XJS** FibroScan○R实施受控衰减参数评价脂肪性肝炎肝纤维化的临床研究 中国肝炎防治基金会 2012-06~2013-12 70万元 课题负责人
2012CB517500 脂代谢紊乱导致脂肪肝及高脂血症发生的机制：遗传学研究 国家科技部973项目课题 2012-01~2017-01 560万元 课题负责人
2011 Nrf2-Keap1系统拮抗胰岛素抵抗依赖性氧化应激对非酒精性脂肪性肝病的防治研究 上海市卫生局新**** 2011-08~2016-07 100万元 课题负责人
** 逆转TLRs/MyD88途径介导的先天免疫功能亢进对NASH的防治作用 国家自然科学基金面上项目 2011-01~2013-12 32万元 课题负责人
上海地区非酒精性脂肪性肝病预警指标体系及其干预模式的筛选和建立 上海市科委重点项目 2010-07~2013-06 20万元 课题负责人
慢性乙型肝炎合并脂肪肝小鼠模型的建立 上海市科委，实验动物资助 2009-09~2011-12 25万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Zou ZY, Wong VS, Epidemiology of nonalcoholic fatty liver disease in non-obese populations: Meta-Analytic Assessment of Prevalence, Genetic, Metabolic and Histological Profiles. J Dig Dis 2020 May 5.doi: 10.1111/1751-2980.
Li J, Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clinical Trans Hepatol 2020 8(1):13-17.
Zeng J, Liu XL, Xin FZ, Zhao ZH, Shao YL, Yang RX, Pan Q, Effects and therapeutic mechanism of YinZhiHuang on high-fat high-cholesterol diet induced steatohepatitis in rats. J Dig Dis. 2020 21(3):179-188
Zou ZY, Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease. J Hepatol. 2020 73:212-214.
Ding WJ, Wu WJ, Chen YW, Chen HB,, Qiao L*. Expression of Notch family is altered in non alcoholic fatty liver disease. Molecular Medicine Reports 2020 22:1702-1708.
Xin FZ, Zhao ZH, Zhang RN, Pan Q, Gong ZZ, Sun C, Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα. World J Gastroenterol. 2020 26(18): 2203-2220.
Zeng J, Yang RX, Pan Q, Zhang RN, Cao HX, Xin FZ, Chen GY, Hu Y, Prevalence, Clinical Characterizations, Risk Factors and Indicators for Lean Chinese Adults with Nonalcoholic Fatty Liver Disease. World J Gastroenterol. 2020 26(15):1792-1804.
Zhao ZH, Xin FZ, Xue YQ, Hu ZM, Han YM, Ma FG, Zhou D, Liu XL, Cui AY, Liu ZS, Liu YX, Gao J, Pan Q, Li Y*, Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019 51(9):103.
Zhu CY, Qu JC, Cao HX, Chen GY, Shi YY, Obesity and non-alcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. Medicine (Baltimore). 2019 98(37):e17098.
Pan Q, Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary Pancreat Dis Int. 2019 18:1-3.
Yang RX, Nitro-oleic acid as a new drug candidate for non-alcoholic steatohepatitis. EBioMedicine. 2019 42:32-33.
Zhou D, Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019 25(17): 2019-2028.
Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, Zeng J, Zhou HP, Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in NAFLD Hepatology 2019 2019 Nov 28 Epub.
Zou ZY, Shen B, Systematic Review with Meta-analysis: Epidemiology of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Mar 27. pii: izz043.
Li YM,, et al. Guideline of prevention and treatment of alcoholic liver disease (2018, China). J Dig Dis. 2019 20(4):174-180.
Zhao ZH, Lai JK, Qiao L, Role of gut microbial metabolites in nonalcoholic fatty liver disease. J Dig Dis. 2019 20(4):181-188.
Zhao ZH, Xin FZ, Zhou D, Xue YQ, Liu XL, Yang RX, Pan Q, Trimethylamine N-Oxide Attenuates High-Fat High-Cholesterol Diet-Induced Steatohepatitis by Reducing Hepatic Cholesterol Overload in Rats. World J Gastroenterol. 2019 25(20):2450-2462.
Shen F, Letter: moderate-to-severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Authors' reply. Aliment Pharmacol Ther. 2019 50(5):617-618.
Yang RX, Pan Q, Liu XL, Zhou D, Xin FZ, Zhao ZH, Zhang RN, Zeng J, Qiao L, Hu CX, Xu GW, Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis. Lipids Health Dis. 2019 18(1):179.
, Wei L, Zhuang H, et al. Guideline of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis. 2019 20(4):163-173.
Shen F, Editorial:effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B- authors’ reply. Aliment Pharmacol Ther. 2019 50(3):334-335.
Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther. 2019 50(1):93-102.
Zeng J, Zhang X, Sun C, Pan Q, Lu WY, Chen Q, Huang LS, Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5?years. BMC Pediatr. 2019 19(1):129.
Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, Zhou H, Sodium butyrate reduces high fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018 50(12):157.
Zhang RN, Pan Q, Zheng RD, Mi YQ, Shen F, Zhou D, Chen GY, Zhu CY, Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies as potential biomarkers of nonalcoholic fatty liver disease. Int J Mol Med 2018 42(1):443-452.
Wu J, Zhang R, Shen F, Yang R, Zhou D, Cao H, Chen G, Pan Q, Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). Med Sci Monit. 2018 24:6946-6967.
Guo XY, Sun F, Chen JN, Wang YQ, Pan Q*, circRNA_** inhibits hepatic steatosis by normalization of PPAR signaling. World J Gastroenterol. 2018 24(3):323-337.
Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017 16(4):375-381.
Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol. 2017 23(1):60-75.
Zeng J, Sun C, Sun WL, Chen GY, Pan Q, Yan SY, Xu ZJ, Chen YW, Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults at a health check-up. J Dig Dis 2017 18(4):229-236.
Pan Q, Chen MM, Zhang RN, Wang YQ, Zheng RD, Mi YQ, Liu WB, Shen F, Su Q, PNPLA3 rs** predisposes chronic hepatitis B to hepatic steatosis, but improves insulin resistance and glucose metabolism. J Diabetes Res. 2017 2017:**.
Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 7(1):1529.
Yan SY,, Qiao L. Hepatitis B virus infection and hepatocellular carcinoma- new insights for an old topic. Current Cancer Drug Target 2017 17(6):505-511.
Zhou D, Pan Q, Liu XL, Yang RX, Chen YW, Liu C, Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J Gastroenterol Hepatol. 2017 32(9):1640-1648.
Li BH, He FP, Yang X, Chen YW, Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. Transl Res. 2017 180: 103-111.
Liu XL, Cao HX, Wang BC, Xin FZ, Zhou D, Zhang RN, Yang RX, Zhao ZH, Pan Q, miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol. 2017 23(46):8140-8151.
Guo XY, Chen J, Sun F, Wang YQ, Pan Q, circRNA-** Prevents hepatoxicity of lipid peroxidation: An inhibitory role against hepatic steatosis. Oxid Med Cell Longev. 2017 2017:**.
Yang RX, Hu CX, Sun WL, Pan Q, Shen F, Yang Z, Su Q, Xu GW, Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B. Sci Rep. 2017 7(1):10517.
, Kim SU, Wong Vincent WS. New Trends on Obesity and NAFLD in Asia. J Hepatol 2017 67:862-873.
Xu L, Lu W,Li P, Shen F,Mi YQ, A comparison of hepatic steatosis index, controlled attenuation parameter, and ultrasound as noninvasive diagnostic tools for hepatic steatosis in patients with biopsy-proven chronic hepatitis B. Dig Liver Dis. 2017 49(8):910-917.
Zhou D, Wang J, He LN, Li BH, Ding YN, Chen YW, Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ. Exp Ther Med. 2017 13(2):780-786.
Guo XY, He CX, Wang YQ, Sun C, Li GM, Su Q, Pan Q, Circular RNA profiling and bioinformatic modeling indentify its regulatory role in hepatic steatosis. Biomed Res Int. 2017 2017:**.
Cao Y, Pan Q, Cai W, Shen F, Chen GY, Xu LM, Modulation of gut microbiota with berberine improves steatohepatitis in high-fat diet-fed BALB/c mice. Arch Iran Med 2016 19(3):197-203.
Yan SY, Zhang Y, Sun C, Cao HX, Li GM, Wang YQ, The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma. Oncol Lett. 2016 12（2）：951-955.
Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, Xu ZJ, Chen YW, Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016 22(44):9844-52.
Zhou D, Li BH, Wang J, Ding YN, Dong Y, Chen YW, Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line. Plos One 2016 11(10):e**.
Zhang RN, Zheng RD, Mi YQ, Zhou D, Shen F, Chen GY, Zhu CY, Pan Q, APOC3 rs** Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. Dig Dis Sci 2016 ;61(8):2284-93.
Yan SY, Zhang Y, Sun C, Cao HX, Li GM, Wang YQ, Comparison of real-time contrast-enhanced ultrasonography and standard ultrasonography in liver cancer microwave ablation. Exp Ther Med. 2016 12(3):1345-1348.
Liu XL, Cao HX, miRNA as diagnostic marker of non-alcoholic steatohepatitis. J Dig Dis 2016 17(11):708-715.
Chen GY, Cao HX, Li F, Cai XB, Ao QH, Gao Y, A new risk scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel Cohort. J Diabetes Investig. 2016 7(2):206-211.
Xu ZJ, Shi JP, Yu DZ, Jia JD, Evaluating the Relationship of Metabolic Syndrome With Liver-Biopsy Proven Non-Alcoholic Steatohepatitis in China: A Multicentre Cross-Sectional Study Design. Adv Ther. 2016 33(11):2069-2081.
Sun C, Wilson GS,, Qiao L. Potential Applications of Induced Pluripotent Stem Cells (iPSCs) in Hepatology Research. Curr Stem Cell Res Ther. 2015 10(3):209-251.
Yang SL, Xia JH, Zhang YY,, Wang H, Yuan J, Zhao ZZ, Pan Q, Mu YL, Xin LL, Chen YX, Li K. Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci Rep 2015 5:13980.
Yan SY, Chen MM, Li GM, Wang YQ, MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumour Biol. 2015 36(6):4747-55.
Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. Liver Int. 2015 35(11): 2392-400.
, Wang FS. Reply Hepatology 2015 62(2):657.
Chen GY, Li L, Dai F, Li XJ, Xu XX, Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. Med Sci Monit 2015 21:2476-2484.
Pan Q, Zhang RN, Wang YQ, Zheng RD, Mi YQ, Liu WB, Shen F, Chen GY, Lu JF, Zhu CY, Zhang SY, Chen YM, Sun WL, Linked PNPLA3 polymorphisms confer susceptibility to nonalcoholic steatohepatitis and decreased viral load in chronic hepatitis B. World J Gastroenterol 2015 21(28):8605-14.
Ge WS, Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis. World J Gastroenterol 2015 21(15):4744-9.
Yan S, Wang Y, Chen M, Li G, Deregulated SLC2A1 Promotes Tumor Cell Proliferation and Metastasis in Gastric Cancer. Int J Mol Sci. 2015 16(7):16144-57.
Ding WJ, Wang MM, Wang GS, Fen S, Qin JJ, Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B infected subjects. J Gastroenterol Hepatol 2015 30(12):1753-1758.
Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Saturated fatty acid Inhibits Viral Replication in Chronic HBV Infection with Nonalcoholic Fatty Liver Disease by TLR4 Mediated Innate Immune Response. Hepat Mon. 2015 15(5):e27909.
Sun C,, Qiao L. Potential epigenetic mechanism in non-alcoholic fatty liver disease. Int J Mol Sci. 2015 16(3):5161-79.
Pan Q, Wang YQ, Li GM, Duan XY, Fuzheng Huayu Recipe Ameliorates liver Fibrosis by Restoring Balance between Epithelial-to-mesenchymal Transition and Mesenchymal-to-epithelial Transition in Hepatic Stellate Cells. BioMed Res Int 2015 2015:**.
Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, Shen F, Lu W, CAP for noninvasive assessment of hepatic steatosis using Fibroscan: Validation in chronic hepatitis B. Dig Dis Sci 2015 60(1):243-51.
Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J Gastroenterol. 2014 20(16):4702-11.
Han Y, Shi JP, Ma AL, Xu Y, Ding XD, Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig. 2014 34(1):1-7.
Cao HX, Zhu KX,, Qiao L. Garlic-derived allyl sulfides in cancer therapy. Anticancer Agents Med Chem 2014 14(6):793-9.
Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Hepatic Steatosis Is Highly Prevalent in Hepatitis B Patients and Negatively Associated with Virological Factors. Dig Dis Sci 2014 59(10):2571-9
Ding WJ, Wang Y, Regulation of Adipokines by Polyunsaturated Fatty Acids in a Rat Model of Non-alcoholic Steatohepatitis. Arch Iran Med. 2014 17(8):563-8.
Duan XY, Zhang L,, Qiao L. NAFLD leads to liver cancer: do we have sufficient evidence? Cancer letter 2014 345(2):230-4.
Wang FS,, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology 2014 60:2099-2108.
Pan Q, Guo C, Sun C,, Fang C. Integrative analysis of the transcriptome and targetome identifies the regulatory network of miR-16: An inhibitory role against the activation of hepatic stellate cells. Biomed Mater Eng. 2014 24(6):3863-71.
Duan XY, Pan Q, Yan SY, Ding WJ, Fan JG, High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma. BMC Gastroenterol. 2014 14(1):195.
Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, Shen F, Lu W, CAP for noninvasive assessment of hepatic steatosis using Fibroscan: Validation in chronic hepatitis B. Dig Dis Sci 2014 59(12):2589-8.
Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013 28(Supple 1):11-17.
, Cao HX. The role of diet and nutritional management of nonalcoholic fatty liver dieases. J Gastroenterol Hepatol. 2013 28(Supple 4):81-87.
Wang B, Li W, Chen Y, Wang Y, Sun C, Chen Y, Lu H,, Li D Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Med Sci Monit. 2012 18(10):394-401
Zhang Z, Pan Q, Duan XY, Liu Q, Mo GY, Rao GR, Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol 2012 27(12):1858-64
Wang B, Li W, Guo K, Xiao Y, Wang Y, miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biophys Res Commun. 2012 421(1):4-8.
Duan XY, Qiao L, Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012 11: 11(1):18-27.
, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of non-alcoholic fatty liver disease: update 2010. J Dig Dis 2011 12:38-44.
Shi JP, Xun YH, Su YX, Jiang YM, Zhang L, Hu CB, Metabolic syndrome and severity of fibrosis in patients with chronic hepatitis B virus infection or nonalcoholic fatty liver disease. J Microbiology Research 2011 5:481-485.
Li YM,, Wang BY, et al. Chinese Guidelines for the diagnosis and management of alcoholic liver disease: update 2010. J Dig Dis 2011 12:45-50.
Cao HX, Fatty liver disease: a growing public health problem worldwide. J Dig Dis 2011 12: 1-2.
Wu JY, Duan XY, Li L, Dai F, Li YY, Li XJ, Dyslipidemia in Shanghai, China. Preventive Medicine 2010 51:412-415.
Duan XY, Zhao XP, Dynamic expression of hepatic thioredoxin mRNA in rats with nonalcoholic fatty liver disease. J Dig Dis 2010 11:94-100.
, Farrell GC. Does NAFLD predispose patients to type 2 diabetes in the absence of obesity? J Gastroenterol Hepatol 2010 25:223-225
A tribute to Dr Guang-bi Yao (1931-2010). J Gastroenterol Hepatol. 2010 25(6):1027-28.
Lin G, Duan XY, Cai XB, XY Tian, ZJ Xu, Hepatocyte steatosis increases the expression of adhesion molecules in endothelial cells. Asian Biomedicine 2010 4:757-763.
Xu ZJ,, et al. Characterization of a high-fat diet-induced non-alcoholic steatohepatitis in rats. Dig Dis Sci. 2010 55:931-40.
, Qiao L. Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int 2009 8:233-240.
, Farrell GC. Prevention of hepatocellular carcinoma in non-viral related liver diseases. J Gastroenterol Hepatol. 2009 24:712-19.
, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009 50:204-10.
, et al. Alcohol consumption and metabolic syndrome among Shanghai adults: A randomized multistage stratified cluster sampling investigation. World J Gastroenterol 2008 14:2418-2424.
, Chitturi S. Hepatitis B and fatty liver: causal or coincidental? J Gastroenterol Hepatol. 2008 23:779-782.
Shi J,, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008 23:1419-1425.
, Farrell GC. VAT fat is bad for the liver, SAT fat is not! J Gastroenterol Hepatol. 2008 23:829-32.
, et al. Alcohol consumption and metabolic syndrome among Shanghai adults: A randomized multistage stratified cluster sampling investigation. World J Gastroenterol 2008 14:2418-2424.
Impact of nonalcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 2008 9:63-67.
, et al. What are the risk factors and settings of nonalcoholic fatty liver disease in Asia-Pacific. J Gastroenterol Hepatol 2007 22:794-800.
, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int 2007 6:572-578.
, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007 22:1086-91.
, et al. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 2007 22:663-668.
, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005 20:1825-1832.
, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005 43:508-514.
, et al. Effect of lactulose on establishment of nonalcoholic steatohepatitis model. World J Gastroenterol 2005 11:5053-5056.
, et al. Effects of UDCA and/or low-calorie diet on steatohepatitis in rats fed a high fat diet. World J Gastroenterol 2005 11:2346-2350.
Qian Y, Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int 2005 4:173-177.
Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with NAFLD: a multicenter clinical trial. Hepatobiliary Pancreat Dis Int 2004 3:375-380
, Zhong L, Xu ZJ, Tia LY, Ding XD, Li MS, Wang GL. Effects of low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia. World J Gastroenterol 2003 9:2045-2049.
Shen L,, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai:an epidemiological survey. World J Gastroenterol 2003 9:1106-1110.
, Chen LH, Xu ZJ, Zeng MD. Over-expression of hepatic PAI-1 mRNA in rabbits with fatty liver. World J Gastroenterol 2001 7:710-712.




相关话题/上海交通大学 医学院
  • 领限时大额优惠券,享本站正版考研考试资料!
    大额优惠券
    优惠券领取后72小时内有效，10万种最新考研考试考证类电子打印资料任你选。涵盖全国500余所院校考研专业课、200多种职业资格考试、1100多种经典教材，产品类型包含电子书、题库、全套资料以及视频，无论您是考研复习、考证刷题，还是考前冲刺等，不同类型的产品可满足您学习上的不同需求。 ...
    考试优惠券 本站小编 Free壹佰分学习网 2022-09-19
  • 上海交通大学医学院导师教师师资介绍简介-张洪梅
    导师姓名：张洪梅专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：内分泌与代谢病导师类型：硕士生导师专业学位导师：兼联系方式：上海市控江路1665号新华医院内分泌科邮编：200092邮箱地址：spicygirlss@126.com研究方向(点击浏览详细信息)糖尿 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-简蔚霞
    导师姓名：简蔚霞专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：内分泌与代谢病导师类型：硕士生导师专业学位导师：兼联系方式：邮编：janewx110@163.com邮箱地址：janewx110@163.com研究方向(点击浏览详细信息)2型糖尿病及其并发症的致 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-杜世春
    导师姓名：杜世春专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：内分泌与代谢病导师类型：硕士生导师专业学位导师：兼联系方式：上海交通大学医学院附属新华医院内分泌科邮编：200092邮箱地址：dushichun211@163.com研究方向(点击浏览详细信息)糖 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-秦利
    导师姓名：秦利专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：内分泌与代谢病导师类型：硕士生导师专业学位导师：兼联系方式：qinli@medmail.com.cn邮编：200092邮箱地址：qinli@medmail.com.cn研究方向(点击浏览详细信息)2 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-杨震
    导师姓名：杨震专业代码：100201性别：男专业名称：内科学培养单位：附属新华医院三级学科/专业领域：内分泌与代谢病导师类型：硕士生导师专业学位导师：联系方式：邮编：邮箱地址：Yangzhen1020@hotmail.com研究方向(点击浏览详细信息)社会任职科研项目学术论文 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-李威
    导师姓名：李威专业代码：100201性别：男专业名称：内科学培养单位：附属新华医院三级学科/专业领域：心血管病导师类型：硕士生导师专业学位导师：兼联系方式：邮编：邮箱地址：lwcbss@163.com研究方向(点击浏览详细信息)心脏电生理与心律失常社会任职上海市心律学会青年委员会委员上海医学会心血管 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-孙莉静
    导师姓名：孙莉静专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：肾病导师类型：硕士生导师专业学位导师：兼联系方式：控江路1665号新华医院6号楼8楼肾内科邮编：200092邮箱地址：sunlijing68@163.com研究方向(点击浏览详细信息)慢性肾脏病营 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-陶荣
    导师姓名：陶荣专业代码：100201性别：男专业名称：内科学培养单位：附属新华医院三级学科/专业领域：血液病导师类型：硕士生导师专业学位导师：联系方式：通讯地址：上海市控江路1665号新华医院血液科Email：hkutao@hotmail.com邮编：200092邮箱地址：hkuta@gmail.c ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-王耀晟
    导师姓名：王耀晟专业代码：100201性别：男专业名称：内科学培养单位：附属新华医院三级学科/专业领域：心血管病导师类型：硕士生导师专业学位导师：联系方式：邮编：200092邮箱地址：wangyaosheng@xinhuamed.com.cn研究方向(点击浏览详细信息)缺血性心肌病分子生物学机制与调 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02
  • 上海交通大学医学院导师教师师资介绍简介-杨玲
    导师姓名：杨玲专业代码：100201性别：女专业名称：内科学培养单位：附属新华医院三级学科/专业领域：呼吸系病导师类型：硕士生导师专业学位导师：兼联系方式：邮编：邮箱地址：yanglingjoy@hotmail.com研究方向(点击浏览详细信息)慢性气道疾病社会任职中国医药教育协会呼吸病康复委员会全 ...
    上海交通大学师资导师 本站小编 Free考研考试 2021-01-02

Free考研考试FreeKaoYan.Com
欢迎来到Free考研考试，"为实现人生的Free而奋斗"

© 2020 FreeKaoYan! . All rights reserved.